A Phase I/II Dose Escalation Trial of Clofarabine, in Addition to Melphalan and Thiotepa as Myeloablative Regimen Followed by an Allogeneic Unmodified Hematopoietic Stem Cell Transplant From HLA-Compatible Related or Unrelated Donors for the Treatment of High Risk and/or Advanced Hematologic Malignancies.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Clofarabine (Primary) ; Melphalan; Thiotepa
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Haematological malignancies; Myelodysplastic syndromes; Myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2021 Biomarkers information updated
- 04 Jun 2013 Planned end date changed from 1 Nov 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
- 03 Dec 2012 Planned end date changed from 1 Nov 2010 to 1 Nov 2013 as reported by ClinicalTrials.gov.